Adequan I.M. (Canada)

This page contains information on Adequan I.M. for veterinary use.
The information provided typically includes the following:

Adequan I.M. Indications
Warnings and cautions for Adequan I.M.
Direction and dosage information for Adequan I.M.

Adequan I.m.

This treatment applies to the following species:

Horses

Manufacturer: Novartis

polysulfated Glycosaminoglycan Injection

100 Mg/ml

for Veterinary Use Only

For Intramuscular Use In Horses

DIN 01910051

Description

Each mL of Adequan^® I.M. contains 100 mg of Polysulfated Glycosaminoglycan (PSGAG) and Water for injection q.s. Sodium hydroxide and/or hydrochloric acid added as necessary to adjust pH. Sodium chloride may be added to adjust tonicity.

Pharmacology

Polysulfated Glycosaminoglycan is chemically similar to the mucopolysaccharides of cartilaginous tissue. It is a potent proteolytic enzyme inhibitor and diminishes or reverses the processes which result in the loss of cartilaginous mucopolysaccharides. PSGAG improves joint function by stimulating synovial membrane activity, reducing synovial protein levels and increasing synovial fluid viscosity in traumatized equine joints.

Toxicity

Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks or a total of 21 injections. This dosage is 5 times the recommended dosage and approximately 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal showed any evidence of abnormality that was related to Adequan^® I.M. treatment as determined by clinical observation and a battery of laboratory tests.

From 100,000 doses used clinically, the reported incidence of side effects is 0.001% (1 case). This reaction consisted of a transient joint flare, occurring within 24 hours of injection, and resolving within 24 hours with anti-inflammatory therapy.

Adequan I.M. Indications

Adequan^® I.M. is recommended for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses.

Contraindications

Do not use Adequan^® I.M. in horses demonstrating hypersensitivity to PSGAG.

Warnings

This drug is not to be administered to horses that are to be slaughtered for use in food. Keep out of the reach of children.

Adequan I.M. Dosage And Administration

The recommended dose of Adequan^® I.M. is 500 mg (1 vial) per 1000 lbs. body weight, given intramuscularly every 4 days for a total of 8 injections over a 28 day period. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan^® I.M. with other drugs or solvents. For intramuscular use only - avoid inadvertent intravascular administration.

Adverse Reactions

There are no known adverse reactions associated with the use of Adequan^® I.M.

Adequan I.M. Caution

Avoid inadvertent intravascular administration. Not intended for use in breeding animals as effects on fertility and reproductive function in mares and stallions have not been studied.

How Supplied

Adequan^® I.M., PSGAG 100 mg/mL, is available in 5 mL single dose vials packaged in boxes of 7.

Storage Conditions

Store at controlled room temperature up to 25°C (77°F).

Discard unused portion.

LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, N.Y. 11967

(1-800-458-0163)

Distributed by: Novartis Animal Health Canada Inc., 2000 Argentia Rd. Suite 400 Plaza 3, Mississauga, Ontario L5N 1V9

IN99501C

Rev. 4/09C

MG #15651

Nac No.

12311020

NOVARTIS ANIMAL HEALTH CANADA INC.
2000 ARGENTIA RD., SUITE 400, PLAZA 3, MISSISSAUGA, ON, L5N 1V9

Telephone:		800-387-6325
Order Desk:		800-387-6325
Fax:		905-567-0221
Fax Orders:		800-827-5782
Website:		www.ah.ca.novartis.com
Email:		ah.questions@novartis.com

Every effort has been made to ensure the accuracy of the Adequan I.M. information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Printable Version

Email Page